Search results
Results From The WOW.Com Content Network
Nandrolone decanoate, sold under the brand names Rolon [7] and Deca-Durabolin, among others, is an androgen and anabolic steroid (AAS) medication which is used primarily in the treatment of anemias and wasting syndromes, as well as osteoporosis in menopausal women.
It is also an anabolic steroid (AAS) which is medically used in the form of esters such as nandrolone decanoate (brand name Deca-Durabolin) and nandrolone phenylpropionate (brand name Durabolin). [ 2 ] [ 12 ] [ 8 ] [ 13 ] Nandrolone esters are used in the treatment of anemias , cachexia ( muscle wasting syndrome), osteoporosis , breast cancer ...
Decabromodiphenyl ether (also referred to as decaBDE, DBDE, BDE-209) is a brominated flame retardant which belongs to the group of polybrominated diphenyl ethers (PBDEs). It was commercialised in the 1970s and was initially thought to be safe, [3] [4] but is now recognised as a hazardous and persistent pollutant.
Deca-, a metric prefix; Nandrolone, the active ingredient in the steroid Deca-Durabolin, commonly referred to as Deca; Decabromodiphenyl ether, an organic compound; Deca-press, Moldavian news agency; Deca (journalism collective), a journalism cooperative; Deca i Sunce (Children and the Sun), album by the Serbian hip-hop artist Marčelo
The idea behind an annual scan is that by gathering a data set every 365 days (or thereabouts), Neko’s team will be able to track and observe fluctuations in your health and advise you on what ...
Risks associated with treatment of late-onset hypogonadism [ edit ] There is a potential concern in the medical community that the administration of testosterone therapy for the treatment of late-onset hypogonadism may escalate the risks associated with benign prostatic hyperplasia , prostate cancer and heart diseases.
Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women.
Side effects of vosilasarm in preliminary clinical studies in women with metastatic breast cancer have included vomiting (27%), dehydration (27%), constipation, decreased appetite and weight loss (27%), hypophosphatemia, decreased sex hormone-binding globulin (SHBG) levels (100%), increased prostate-specific antigen (PSA) levels (80%), and abnormal liver function tests, including elevated ...